Affimed NV (LTS:0HL9)
$ 2.22 0.1082 (4.73%) Market Cap: 38.03 Mil Enterprise Value: 25.31 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 26/100

Affimed NV at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 12:30PM GMT
Release Date Price: $7.64 (-1.61%)
Maury Raycroft
Jefferies, LLC - Analyst

Good morning, everyone. I'm Maury Raycroft, one of the biotech analysts at Jefferies, and it's with great pleasure that I'd like to welcome Adi Hoess, the CEO of Affimed. Thanks so much for joining us today, Adi.

Adi Hoess
Affimed NV - CEO

Good morning, Maury. Thanks so much for the invitation. Happy to be here.

Maury Raycroft
Jefferies, LLC - Analyst

And today, we're going to do a fireside chat. So maybe for those who are new to the story, if you can provide a one-minute intro to Affimed.

Adi Hoess
Affimed NV - CEO

Yeah. Affimed is a company that develops multi-specific antibodies. The intent is to activate the innate immune system, specifically NK cells and macrophages.

We are doing this in three ways: we use the innate cell engagers basically to power up, enhance the efficacy of natural killer cells; we use the innate cell engagers to not only activate innate immunity, but also adaptive immunity. So hence, we have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot